- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
FDA Grants Clearance for Use of Hemostatic Gel Technology
Cresilon, Inc., developed the gel that can control the bleeding from a wound without having to apply pressure.
Joe Landolina
CEO and co-founder
Cresilon
The FDA granted Creilon’s Homestatic Gel 501(k) clearance. According to a press release from Cresilon, this is the first product from the company to receive clearance for human use.
The company developed the gel to be used for wound treatment. It can reportedly control bleeding from an open wound without requiring any pressure to be applied. According to Cresilon, the gel is for prescription use only.
In a press release, Joe Landolina, Cresilion CEO and co-founder, said, “The combination of these unique attributes will allow our technology to fill a critical unmet medical need while creating a significant and positive impact in helping to save lives and dramatically improving the standard of care in wound treatment. The FDA clearance sets the predicate for our advanced technology and marks Cresilon's first step towards actualizing our long-term goal of expanding our technology within the broader human health market."
Cresilon is a Brooklyn-based company that is focused on developing treatments that use the company’s proprietary hydrogel technology.
